Opinion|Videos|July 8, 2024
Key Findings from the INTERCEPT Study
Author(s)Stacey A. Cohen, MD, Daniel H. Ahn, DO
GI medical oncologists review recent findings from the INTERCEPT study evaluating the prognostic performance of circulating tumor DNA in clinical practice.
Advertisement
Episodes in this series
Advertisement
Related to this article
More than two-thirds of patients with mismatch repair–deficient locally advanced rectal cancer achieved a clinical complete response with dostarlimab alone.
Advertisement
Advertisement
Trending on CancerNetwork
1
Biomarker Sequencing, PD-L1 Status, and FLOT Dosing in Gastroesophageal Cancer
2
CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma
3
Setting Up an HDR Brachytherapy Program Amid a National Decline
4
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
5